NasdaqGM - Nasdaq Real Time Price • USD
MannKind Corporation (MNKD)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:19 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 0.03 | 0.03 | 0.13 | 0.25 |
| Low Estimate | 0.01 | 0.01 | 0.06 | 0.14 |
| High Estimate | 0.04 | 0.06 | 0.26 | 0.36 |
| Year Ago EPS | -0.04 | -0.02 | -0.04 | 0.13 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 60.49M | 63.72M | 259.92M | 319.91M |
| Low Estimate | 56.6M | 59.5M | 241.5M | 280.13M |
| High Estimate | 66.71M | 74.46M | 308.53M | 368.82M |
| Year Ago Sales | -- | 48.61M | 198.96M | 259.92M |
| Sales Growth (year/est) | -- | 31.10% | 30.60% | 23.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.05 | -0.04 | -0.02 | 0 |
| EPS Actual | -0.04 | -0.02 | 0.01 | 0 |
| Difference | 0.01 | 0.02 | 0.03 | 0 |
| Surprise % | 20.00% | 50.00% | 150.00% | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.03 | 0.03 | 0.13 | 0.25 |
| 7 Days Ago | 0.03 | 0.03 | 0.13 | 0.25 |
| 30 Days Ago | 0.03 | 0.03 | 0.1 | 0.25 |
| 60 Days Ago | 0.01 | 0.02 | 0.09 | 0.22 |
| 90 Days Ago | 0.01 | 0.01 | 0.09 | 0.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MNKD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 175.00% | -- | -- | 1.60% |
| Next Qtr. | 250.00% | -- | -- | 10.50% |
| Current Year | 425.00% | -- | -- | 5.20% |
| Next Year | 92.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 35.60% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/15/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 |
| Initiated | Wedbush: Outperform | 10/10/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 8/8/2023 |
Related Tickers
UTHR United Therapeutics Corporation
237.93
+0.42%
LQDA Liquidia Corporation
13.29
-3.77%
ACAD ACADIA Pharmaceuticals Inc.
16.82
-1.46%
CLDX Celldex Therapeutics, Inc.
37.98
-1.43%
IOVA Iovance Biotherapeutics, Inc.
11.31
-3.50%
KNSA Kiniksa Pharmaceuticals, Ltd.
16.91
+0.18%
RIGL Rigel Pharmaceuticals, Inc.
1.0800
+2.86%
NKTR Nektar Therapeutics
1.2400
-6.06%
PBYI Puma Biotechnology, Inc.
5.01
+0.40%
IDYA IDEAYA Biosciences, Inc.
37.13
-1.30%